Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
about
Anxiety in Parkinson's disease: identification and managementMelatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor SymptomsNeural mechanisms underlying stress resilience in Ahi1 knockout mice: relevance to neuropsychiatric disordersAnxiety- and depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson's disease.Does anxiety cause freezing of gait in Parkinson's disease?Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's diseaseSPECT molecular imaging in Parkinson's diseaseThe Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's DiseaseREM sleep deprivation promotes a dopaminergic influence in the striatal MT2 anxiolytic-like effectsRecent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesisClinical issues in the treatment of anxiety and depression in older adults with Parkinson's disease.Psychiatric neural networks and neuropharmacology: Selected advances and novel implicationsThe clinical spectrum of anxiety in Parkinson's disease.Management of anxiety and motor symptoms in Parkinson's disease.Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.Selective dysfunction of basal ganglia subterritories: From movement to behavioral disorders.Neuropathobiology of non-motor symptoms in Parkinson disease.Neuropsychiatric Issues in Parkinson's Disease.Motion and emotion: anxiety-axial connections in Parkinson's disease.Cognitive Function in Parkinson's Disease Patients with and without AnxietyAnxiety and depression in Parkinson's disease.Influence of Mild Cognitive Impairment, Depression, and Anxiety on the Quality of Life of Patients with Parkinson Disease.Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.The impact of motor symptoms on self-reported anxiety in Parkinson's disease.Variables associated with physical health-related quality of life in Parkinson's disease patients presenting for deep brain stimulation.Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease.Risky decision-making and affective features of impulse control disorders in Parkinson's disease.The relation of anxiety and cognition in Parkinson's disease.The effects of anxiety and external attentional focus on postural control in patients with Parkinson's disease.Transcranial midbrain sonography and depressive symptoms in patients with Parkinson's disease.Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction.Paraventricular hypothalamic and amygdalar CRF neurons synapse in the external globus pallidus.The relationship between stress and Alzheimer's disease.Anxiety and depression in individuals with Parkinson's disease: perspectives of the nurse specialist
P2860
Q27020996-FD84ADCC-B050-4ECB-AFF6-04603F12198AQ28075345-8497FD3A-FD6F-414D-AC8B-54F1C5DCCBA3Q29036263-DF7FB3DC-1928-4DB5-922D-35EB8B2E0457Q30438962-C4AC5860-6FF9-4A56-B35F-C217D1E230F9Q34243678-088C3BB5-4F97-4F5B-B081-CE43D789F7B7Q34654923-7D9D3208-70BC-4533-ACB8-0E777FEE76C7Q35875725-D745C750-114A-4623-88BC-8910E2199A63Q36494212-476E1351-7A93-46E0-92FC-38C60020050FQ36903829-C82F394B-627F-4596-A8CB-59D5F812858FQ37999106-A61562A5-C9EB-4F17-BE62-E4EE834D4ABAQ38128462-20B21A13-D263-42C3-8C5D-065F3F67E11EQ38152373-DF070B44-A121-42E4-92E5-FEFA9A76D476Q38197608-8B63C727-9FF7-4918-BA7D-48D87B9BB6FBQ38231914-47EF1B93-1960-4DA7-B0BD-9A1FD2C19423Q38233285-E585BBA0-774B-41A2-8685-B37D168145AFQ38366271-809E1546-8146-43BE-98C0-60531AE9F456Q38378640-787BE1E6-06D4-4AF3-A279-C185286B7505Q38481481-90EBF8D8-0D46-4F20-A1D9-42B133B01655Q38799051-0654F8A4-64A3-4B36-B09C-D22BEF2E852AQ39160382-B2B5D149-D197-419E-8819-484097C0B7EDQ41540738-015913D5-02A9-4D5C-9463-0349E83ECDD5Q43491031-EC856F96-FEBA-49FA-9DB3-4C30B945717BQ45124937-17573EA8-7046-4D45-8D78-C0C6F83733A6Q46814011-6DC351AD-2CFC-4D9B-A684-E79B12500ACDQ47338795-038890B7-3AD0-4A50-BEDF-33E3CDED4B3BQ47689941-9C84D8FA-0B92-4514-A913-A1E9ADEBC627Q47711715-CF41B7C0-9742-45A2-BDCA-F8BA2865726DQ47714523-8F871173-203A-43DA-8E51-41C0BCEC8876Q47744162-8E633396-E997-423A-916C-F42C7FF62158Q48042463-94B6CF26-4A06-4213-992B-D8EF0CB7390FQ48140796-94873B6D-1A59-4389-B3E8-87DF72AC2579Q48593238-E2E01BBB-F87B-4341-BDF4-B9558AFB4244Q52641230-5C7A4A5E-6763-4380-8DD6-112AE262F149Q55177547-ACF1AF27-B44F-4AF6-815F-4CB2C1194920Q57554121-A48DF35F-A26C-4769-8E34-1CFF4F777DF7
P2860
Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
@en
Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
@nl
type
label
Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
@en
Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
@nl
prefLabel
Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
@en
Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
@nl
P2093
P1433
P1476
Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
@en
P2093
Filipe C Matheus
Marcelo L Schwarzbold
Marcelo M S Lima
Maria A B F Vital
Rui D S Prediger
P304
P356
10.1016/J.NEUROPHARM.2011.08.039
P577
2011-08-31T00:00:00Z